nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Rosuvastatin—atherosclerosis	0.0612	0.211	CbGbCtD
Everolimus—CYP3A4—Ezetimibe—atherosclerosis	0.0612	0.211	CbGbCtD
Everolimus—CYP3A4—Simvastatin—atherosclerosis	0.0569	0.196	CbGbCtD
Everolimus—CYP3A4—Pravastatin—atherosclerosis	0.0557	0.192	CbGbCtD
Everolimus—CYP3A4—Lovastatin—atherosclerosis	0.0557	0.192	CbGbCtD
Everolimus—MTOR—leg—atherosclerosis	0.024	0.225	CbGeAlD
Everolimus—MTOR—hindlimb—atherosclerosis	0.0215	0.201	CbGeAlD
Everolimus—MTOR—appendage—atherosclerosis	0.0184	0.173	CbGeAlD
Everolimus—MTOR—blood vessel—atherosclerosis	0.0103	0.0961	CbGeAlD
Everolimus—MTOR—connective tissue—atherosclerosis	0.00526	0.0493	CbGeAlD
Everolimus—FKBP1A—connective tissue—atherosclerosis	0.00473	0.0443	CbGeAlD
Everolimus—MTOR—cardiovascular system—atherosclerosis	0.00457	0.0429	CbGeAlD
Everolimus—FKBP1A—cardiovascular system—atherosclerosis	0.00411	0.0386	CbGeAlD
Everolimus—MTOR—adipose tissue—atherosclerosis	0.00403	0.0378	CbGeAlD
Everolimus—FKBP1A—adipose tissue—atherosclerosis	0.00363	0.034	CbGeAlD
Everolimus—MTOR—liver—atherosclerosis	0.00283	0.0265	CbGeAlD
Everolimus—FKBP1A—liver—atherosclerosis	0.00254	0.0238	CbGeAlD
Everolimus—CYP3A4—liver—atherosclerosis	0.000831	0.00779	CbGeAlD
Everolimus—Flatulence—Ezetimibe—atherosclerosis	0.0006	0.00158	CcSEcCtD
Everolimus—Pharyngitis—Pravastatin—atherosclerosis	0.000598	0.00157	CcSEcCtD
Everolimus—Chills—Simvastatin—atherosclerosis	0.000598	0.00157	CcSEcCtD
Everolimus—Muscle spasms—Lovastatin—atherosclerosis	0.000597	0.00157	CcSEcCtD
Everolimus—Infection—Rosuvastatin—atherosclerosis	0.000594	0.00156	CcSEcCtD
Everolimus—Alopecia—Simvastatin—atherosclerosis	0.000589	0.00155	CcSEcCtD
Everolimus—Back pain—Ezetimibe—atherosclerosis	0.000589	0.00155	CcSEcCtD
Everolimus—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000586	0.00154	CcSEcCtD
Everolimus—Muscle spasms—Ezetimibe—atherosclerosis	0.000585	0.00154	CcSEcCtD
Everolimus—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000585	0.00154	CcSEcCtD
Everolimus—Vision blurred—Lovastatin—atherosclerosis	0.000585	0.00154	CcSEcCtD
Everolimus—Mental disorder—Simvastatin—atherosclerosis	0.000584	0.00153	CcSEcCtD
Everolimus—Tremor—Lovastatin—atherosclerosis	0.000581	0.00153	CcSEcCtD
Everolimus—Erythema—Simvastatin—atherosclerosis	0.00058	0.00152	CcSEcCtD
Everolimus—Ill-defined disorder—Lovastatin—atherosclerosis	0.000576	0.00151	CcSEcCtD
Everolimus—Eye disorder—Niacin—atherosclerosis	0.000572	0.0015	CcSEcCtD
Everolimus—Flatulence—Simvastatin—atherosclerosis	0.000572	0.0015	CcSEcCtD
Everolimus—Dysgeusia—Simvastatin—atherosclerosis	0.000568	0.00149	CcSEcCtD
Everolimus—Flushing—Niacin—atherosclerosis	0.000568	0.00149	CcSEcCtD
Everolimus—Angioedema—Lovastatin—atherosclerosis	0.000567	0.00149	CcSEcCtD
Everolimus—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000565	0.00148	CcSEcCtD
Everolimus—Anaemia—Ezetimibe—atherosclerosis	0.000562	0.00148	CcSEcCtD
Everolimus—Malaise—Lovastatin—atherosclerosis	0.00056	0.00147	CcSEcCtD
Everolimus—Flushing—Pravastatin—atherosclerosis	0.000559	0.00147	CcSEcCtD
Everolimus—Cardiac disorder—Pravastatin—atherosclerosis	0.000559	0.00147	CcSEcCtD
Everolimus—Muscle spasms—Simvastatin—atherosclerosis	0.000558	0.00147	CcSEcCtD
Everolimus—Angioedema—Ezetimibe—atherosclerosis	0.000556	0.00146	CcSEcCtD
Everolimus—Angiopathy—Niacin—atherosclerosis	0.000555	0.00146	CcSEcCtD
Everolimus—Leukopenia—Lovastatin—atherosclerosis	0.000555	0.00146	CcSEcCtD
Everolimus—Chills—Niacin—atherosclerosis	0.000549	0.00144	CcSEcCtD
Everolimus—Malaise—Ezetimibe—atherosclerosis	0.000549	0.00144	CcSEcCtD
Everolimus—Vision blurred—Simvastatin—atherosclerosis	0.000547	0.00144	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000544	0.00143	CcSEcCtD
Everolimus—Tremor—Simvastatin—atherosclerosis	0.000544	0.00143	CcSEcCtD
Everolimus—Alopecia—Niacin—atherosclerosis	0.000541	0.00142	CcSEcCtD
Everolimus—Chills—Pravastatin—atherosclerosis	0.000541	0.00142	CcSEcCtD
Everolimus—Insomnia—Rosuvastatin—atherosclerosis	0.00054	0.00142	CcSEcCtD
Everolimus—Ill-defined disorder—Simvastatin—atherosclerosis	0.000538	0.00141	CcSEcCtD
Everolimus—Palpitations—Ezetimibe—atherosclerosis	0.000538	0.00141	CcSEcCtD
Everolimus—Paraesthesia—Rosuvastatin—atherosclerosis	0.000537	0.00141	CcSEcCtD
Everolimus—Anaemia—Simvastatin—atherosclerosis	0.000536	0.00141	CcSEcCtD
Everolimus—Malnutrition—Niacin—atherosclerosis	0.000533	0.0014	CcSEcCtD
Everolimus—Erythema—Niacin—atherosclerosis	0.000533	0.0014	CcSEcCtD
Everolimus—Alopecia—Pravastatin—atherosclerosis	0.000533	0.0014	CcSEcCtD
Everolimus—Cough—Ezetimibe—atherosclerosis	0.000531	0.0014	CcSEcCtD
Everolimus—Angioedema—Simvastatin—atherosclerosis	0.00053	0.00139	CcSEcCtD
Everolimus—Arthralgia—Lovastatin—atherosclerosis	0.000528	0.00139	CcSEcCtD
Everolimus—Chest pain—Lovastatin—atherosclerosis	0.000528	0.00139	CcSEcCtD
Everolimus—Myalgia—Lovastatin—atherosclerosis	0.000528	0.00139	CcSEcCtD
Everolimus—Anxiety—Lovastatin—atherosclerosis	0.000526	0.00138	CcSEcCtD
Everolimus—Dyspepsia—Rosuvastatin—atherosclerosis	0.000526	0.00138	CcSEcCtD
Everolimus—Hypertension—Ezetimibe—atherosclerosis	0.000525	0.00138	CcSEcCtD
Everolimus—Flatulence—Niacin—atherosclerosis	0.000525	0.00138	CcSEcCtD
Everolimus—Malaise—Simvastatin—atherosclerosis	0.000523	0.00138	CcSEcCtD
Everolimus—Discomfort—Lovastatin—atherosclerosis	0.000522	0.00137	CcSEcCtD
Everolimus—Leukopenia—Simvastatin—atherosclerosis	0.000519	0.00137	CcSEcCtD
Everolimus—Arthralgia—Ezetimibe—atherosclerosis	0.000518	0.00136	CcSEcCtD
Everolimus—Chest pain—Ezetimibe—atherosclerosis	0.000518	0.00136	CcSEcCtD
Everolimus—Myalgia—Ezetimibe—atherosclerosis	0.000518	0.00136	CcSEcCtD
Everolimus—Flatulence—Pravastatin—atherosclerosis	0.000517	0.00136	CcSEcCtD
Everolimus—Dry mouth—Lovastatin—atherosclerosis	0.000517	0.00136	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000515	0.00135	CcSEcCtD
Everolimus—Dysgeusia—Pravastatin—atherosclerosis	0.000514	0.00135	CcSEcCtD
Everolimus—Muscle spasms—Niacin—atherosclerosis	0.000512	0.00135	CcSEcCtD
Everolimus—Discomfort—Ezetimibe—atherosclerosis	0.000512	0.00135	CcSEcCtD
Everolimus—Pain—Rosuvastatin—atherosclerosis	0.000511	0.00134	CcSEcCtD
Everolimus—Constipation—Rosuvastatin—atherosclerosis	0.000511	0.00134	CcSEcCtD
Everolimus—Dry mouth—Ezetimibe—atherosclerosis	0.000507	0.00133	CcSEcCtD
Everolimus—Muscle spasms—Pravastatin—atherosclerosis	0.000504	0.00133	CcSEcCtD
Everolimus—Infection—Lovastatin—atherosclerosis	0.000503	0.00132	CcSEcCtD
Everolimus—Vision blurred—Niacin—atherosclerosis	0.000502	0.00132	CcSEcCtD
Everolimus—Thrombocytopenia—Lovastatin—atherosclerosis	0.000496	0.0013	CcSEcCtD
Everolimus—Vision blurred—Pravastatin—atherosclerosis	0.000494	0.0013	CcSEcCtD
Everolimus—Arthralgia—Simvastatin—atherosclerosis	0.000494	0.0013	CcSEcCtD
Everolimus—Chest pain—Simvastatin—atherosclerosis	0.000494	0.0013	CcSEcCtD
Everolimus—Myalgia—Simvastatin—atherosclerosis	0.000494	0.0013	CcSEcCtD
Everolimus—Infection—Ezetimibe—atherosclerosis	0.000493	0.0013	CcSEcCtD
Everolimus—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000492	0.00129	CcSEcCtD
Everolimus—Anxiety—Simvastatin—atherosclerosis	0.000492	0.00129	CcSEcCtD
Everolimus—Tremor—Pravastatin—atherosclerosis	0.000492	0.00129	CcSEcCtD
Everolimus—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000489	0.00128	CcSEcCtD
Everolimus—Discomfort—Simvastatin—atherosclerosis	0.000488	0.00128	CcSEcCtD
Everolimus—Nervous system disorder—Ezetimibe—atherosclerosis	0.000487	0.00128	CcSEcCtD
Everolimus—Angioedema—Niacin—atherosclerosis	0.000487	0.00128	CcSEcCtD
Everolimus—Ill-defined disorder—Pravastatin—atherosclerosis	0.000487	0.00128	CcSEcCtD
Everolimus—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000486	0.00128	CcSEcCtD
Everolimus—Anaemia—Pravastatin—atherosclerosis	0.000485	0.00127	CcSEcCtD
Everolimus—Anorexia—Lovastatin—atherosclerosis	0.000483	0.00127	CcSEcCtD
Everolimus—Skin disorder—Ezetimibe—atherosclerosis	0.000482	0.00127	CcSEcCtD
Everolimus—Angioedema—Pravastatin—atherosclerosis	0.000479	0.00126	CcSEcCtD
Everolimus—Syncope—Niacin—atherosclerosis	0.000478	0.00126	CcSEcCtD
Everolimus—Leukopenia—Niacin—atherosclerosis	0.000477	0.00125	CcSEcCtD
Everolimus—Oedema—Simvastatin—atherosclerosis	0.000474	0.00124	CcSEcCtD
Everolimus—Malaise—Pravastatin—atherosclerosis	0.000473	0.00124	CcSEcCtD
Everolimus—Abdominal pain—Rosuvastatin—atherosclerosis	0.000472	0.00124	CcSEcCtD
Everolimus—Palpitations—Niacin—atherosclerosis	0.000471	0.00124	CcSEcCtD
Everolimus—Infection—Simvastatin—atherosclerosis	0.000471	0.00124	CcSEcCtD
Everolimus—Leukopenia—Pravastatin—atherosclerosis	0.00047	0.00123	CcSEcCtD
Everolimus—Loss of consciousness—Niacin—atherosclerosis	0.000468	0.00123	CcSEcCtD
Everolimus—Cough—Niacin—atherosclerosis	0.000465	0.00122	CcSEcCtD
Everolimus—Thrombocytopenia—Simvastatin—atherosclerosis	0.000464	0.00122	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000461	0.00121	CcSEcCtD
Everolimus—Insomnia—Lovastatin—atherosclerosis	0.000458	0.0012	CcSEcCtD
Everolimus—Cough—Pravastatin—atherosclerosis	0.000458	0.0012	CcSEcCtD
Everolimus—Paraesthesia—Lovastatin—atherosclerosis	0.000455	0.00119	CcSEcCtD
Everolimus—Arthralgia—Niacin—atherosclerosis	0.000454	0.00119	CcSEcCtD
Everolimus—Myalgia—Niacin—atherosclerosis	0.000454	0.00119	CcSEcCtD
Everolimus—Hypertension—Pravastatin—atherosclerosis	0.000453	0.00119	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000453	0.00119	CcSEcCtD
Everolimus—Anorexia—Simvastatin—atherosclerosis	0.000451	0.00119	CcSEcCtD
Everolimus—Dyspnoea—Lovastatin—atherosclerosis	0.000451	0.00119	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000451	0.00118	CcSEcCtD
Everolimus—Insomnia—Ezetimibe—atherosclerosis	0.000449	0.00118	CcSEcCtD
Everolimus—Arthralgia—Pravastatin—atherosclerosis	0.000447	0.00117	CcSEcCtD
Everolimus—Myalgia—Pravastatin—atherosclerosis	0.000447	0.00117	CcSEcCtD
Everolimus—Chest pain—Pravastatin—atherosclerosis	0.000447	0.00117	CcSEcCtD
Everolimus—Paraesthesia—Ezetimibe—atherosclerosis	0.000446	0.00117	CcSEcCtD
Everolimus—Dyspepsia—Lovastatin—atherosclerosis	0.000446	0.00117	CcSEcCtD
Everolimus—Anxiety—Pravastatin—atherosclerosis	0.000445	0.00117	CcSEcCtD
Everolimus—Dry mouth—Niacin—atherosclerosis	0.000444	0.00117	CcSEcCtD
Everolimus—Dyspnoea—Ezetimibe—atherosclerosis	0.000443	0.00116	CcSEcCtD
Everolimus—Discomfort—Pravastatin—atherosclerosis	0.000441	0.00116	CcSEcCtD
Everolimus—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00044	0.00116	CcSEcCtD
Everolimus—Decreased appetite—Lovastatin—atherosclerosis	0.00044	0.00116	CcSEcCtD
Everolimus—Dyspepsia—Ezetimibe—atherosclerosis	0.000437	0.00115	CcSEcCtD
Everolimus—Fatigue—Lovastatin—atherosclerosis	0.000437	0.00115	CcSEcCtD
Everolimus—Oedema—Niacin—atherosclerosis	0.000435	0.00114	CcSEcCtD
Everolimus—Pain—Lovastatin—atherosclerosis	0.000433	0.00114	CcSEcCtD
Everolimus—Constipation—Lovastatin—atherosclerosis	0.000433	0.00114	CcSEcCtD
Everolimus—Decreased appetite—Ezetimibe—atherosclerosis	0.000432	0.00113	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000432	0.00113	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000429	0.00113	CcSEcCtD
Everolimus—Asthenia—Rosuvastatin—atherosclerosis	0.000429	0.00113	CcSEcCtD
Everolimus—Insomnia—Simvastatin—atherosclerosis	0.000428	0.00113	CcSEcCtD
Everolimus—Oedema—Pravastatin—atherosclerosis	0.000428	0.00113	CcSEcCtD
Everolimus—Fatigue—Ezetimibe—atherosclerosis	0.000428	0.00113	CcSEcCtD
Everolimus—Shock—Niacin—atherosclerosis	0.000428	0.00112	CcSEcCtD
Everolimus—Infection—Pravastatin—atherosclerosis	0.000425	0.00112	CcSEcCtD
Everolimus—Paraesthesia—Simvastatin—atherosclerosis	0.000425	0.00112	CcSEcCtD
Everolimus—Pain—Ezetimibe—atherosclerosis	0.000425	0.00112	CcSEcCtD
Everolimus—Constipation—Ezetimibe—atherosclerosis	0.000425	0.00112	CcSEcCtD
Everolimus—Tachycardia—Niacin—atherosclerosis	0.000424	0.00112	CcSEcCtD
Everolimus—Pruritus—Rosuvastatin—atherosclerosis	0.000423	0.00111	CcSEcCtD
Everolimus—Skin disorder—Niacin—atherosclerosis	0.000422	0.00111	CcSEcCtD
Everolimus—Dyspnoea—Simvastatin—atherosclerosis	0.000422	0.00111	CcSEcCtD
Everolimus—Hyperhidrosis—Niacin—atherosclerosis	0.00042	0.0011	CcSEcCtD
Everolimus—Thrombocytopenia—Pravastatin—atherosclerosis	0.000419	0.0011	CcSEcCtD
Everolimus—Feeling abnormal—Lovastatin—atherosclerosis	0.000417	0.0011	CcSEcCtD
Everolimus—Dyspepsia—Simvastatin—atherosclerosis	0.000417	0.0011	CcSEcCtD
Everolimus—Anorexia—Niacin—atherosclerosis	0.000415	0.00109	CcSEcCtD
Everolimus—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000414	0.00109	CcSEcCtD
Everolimus—Hyperhidrosis—Pravastatin—atherosclerosis	0.000414	0.00109	CcSEcCtD
Everolimus—Decreased appetite—Simvastatin—atherosclerosis	0.000412	0.00108	CcSEcCtD
Everolimus—Feeling abnormal—Ezetimibe—atherosclerosis	0.000409	0.00108	CcSEcCtD
Everolimus—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000409	0.00107	CcSEcCtD
Everolimus—Diarrhoea—Rosuvastatin—atherosclerosis	0.000409	0.00107	CcSEcCtD
Everolimus—Fatigue—Simvastatin—atherosclerosis	0.000408	0.00107	CcSEcCtD
Everolimus—Anorexia—Pravastatin—atherosclerosis	0.000408	0.00107	CcSEcCtD
Everolimus—Hypotension—Niacin—atherosclerosis	0.000406	0.00107	CcSEcCtD
Everolimus—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000406	0.00107	CcSEcCtD
Everolimus—Pain—Simvastatin—atherosclerosis	0.000405	0.00106	CcSEcCtD
Everolimus—Constipation—Simvastatin—atherosclerosis	0.000405	0.00106	CcSEcCtD
Everolimus—Abdominal pain—Lovastatin—atherosclerosis	0.0004	0.00105	CcSEcCtD
Everolimus—Body temperature increased—Lovastatin—atherosclerosis	0.0004	0.00105	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000396	0.00104	CcSEcCtD
Everolimus—Dizziness—Rosuvastatin—atherosclerosis	0.000395	0.00104	CcSEcCtD
Everolimus—Insomnia—Niacin—atherosclerosis	0.000393	0.00103	CcSEcCtD
Everolimus—Body temperature increased—Ezetimibe—atherosclerosis	0.000393	0.00103	CcSEcCtD
Everolimus—Abdominal pain—Ezetimibe—atherosclerosis	0.000393	0.00103	CcSEcCtD
Everolimus—Paraesthesia—Niacin—atherosclerosis	0.000391	0.00103	CcSEcCtD
Everolimus—Feeling abnormal—Simvastatin—atherosclerosis	0.00039	0.00103	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00039	0.00103	CcSEcCtD
Everolimus—Dyspnoea—Niacin—atherosclerosis	0.000388	0.00102	CcSEcCtD
Everolimus—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000387	0.00102	CcSEcCtD
Everolimus—Insomnia—Pravastatin—atherosclerosis	0.000387	0.00102	CcSEcCtD
Everolimus—Somnolence—Niacin—atherosclerosis	0.000387	0.00102	CcSEcCtD
Everolimus—Paraesthesia—Pravastatin—atherosclerosis	0.000385	0.00101	CcSEcCtD
Everolimus—Dyspepsia—Niacin—atherosclerosis	0.000383	0.00101	CcSEcCtD
Everolimus—Dyspnoea—Pravastatin—atherosclerosis	0.000382	0.001	CcSEcCtD
Everolimus—Decreased appetite—Niacin—atherosclerosis	0.000378	0.000993	CcSEcCtD
Everolimus—Dyspepsia—Pravastatin—atherosclerosis	0.000377	0.00099	CcSEcCtD
Everolimus—Rash—Rosuvastatin—atherosclerosis	0.000377	0.00099	CcSEcCtD
Everolimus—Dermatitis—Rosuvastatin—atherosclerosis	0.000376	0.000989	CcSEcCtD
Everolimus—Gastrointestinal disorder—Niacin—atherosclerosis	0.000375	0.000987	CcSEcCtD
Everolimus—Abdominal pain—Simvastatin—atherosclerosis	0.000374	0.000984	CcSEcCtD
Everolimus—Body temperature increased—Simvastatin—atherosclerosis	0.000374	0.000984	CcSEcCtD
Everolimus—Headache—Rosuvastatin—atherosclerosis	0.000374	0.000984	CcSEcCtD
Everolimus—Hypersensitivity—Lovastatin—atherosclerosis	0.000373	0.00098	CcSEcCtD
Everolimus—Decreased appetite—Pravastatin—atherosclerosis	0.000372	0.000978	CcSEcCtD
Everolimus—Pain—Niacin—atherosclerosis	0.000372	0.000977	CcSEcCtD
Everolimus—Fatigue—Pravastatin—atherosclerosis	0.000369	0.00097	CcSEcCtD
Everolimus—Constipation—Pravastatin—atherosclerosis	0.000366	0.000962	CcSEcCtD
Everolimus—Pain—Pravastatin—atherosclerosis	0.000366	0.000962	CcSEcCtD
Everolimus—Hypersensitivity—Ezetimibe—atherosclerosis	0.000366	0.000962	CcSEcCtD
Everolimus—Asthenia—Lovastatin—atherosclerosis	0.000363	0.000955	CcSEcCtD
Everolimus—Pruritus—Lovastatin—atherosclerosis	0.000358	0.000941	CcSEcCtD
Everolimus—Asthenia—Ezetimibe—atherosclerosis	0.000356	0.000936	CcSEcCtD
Everolimus—Gastrointestinal pain—Niacin—atherosclerosis	0.000356	0.000934	CcSEcCtD
Everolimus—Nausea—Rosuvastatin—atherosclerosis	0.000355	0.000933	CcSEcCtD
Everolimus—Feeling abnormal—Pravastatin—atherosclerosis	0.000353	0.000927	CcSEcCtD
Everolimus—Pruritus—Ezetimibe—atherosclerosis	0.000351	0.000923	CcSEcCtD
Everolimus—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00035	0.00092	CcSEcCtD
Everolimus—Hypersensitivity—Simvastatin—atherosclerosis	0.000349	0.000917	CcSEcCtD
Everolimus—Diarrhoea—Lovastatin—atherosclerosis	0.000346	0.00091	CcSEcCtD
Everolimus—Abdominal pain—Niacin—atherosclerosis	0.000344	0.000903	CcSEcCtD
Everolimus—Body temperature increased—Niacin—atherosclerosis	0.000344	0.000903	CcSEcCtD
Everolimus—Asthenia—Simvastatin—atherosclerosis	0.00034	0.000893	CcSEcCtD
Everolimus—Diarrhoea—Ezetimibe—atherosclerosis	0.00034	0.000893	CcSEcCtD
Everolimus—Body temperature increased—Pravastatin—atherosclerosis	0.000339	0.000889	CcSEcCtD
Everolimus—Abdominal pain—Pravastatin—atherosclerosis	0.000339	0.000889	CcSEcCtD
Everolimus—Pruritus—Simvastatin—atherosclerosis	0.000335	0.000881	CcSEcCtD
Everolimus—Dizziness—Lovastatin—atherosclerosis	0.000335	0.00088	CcSEcCtD
Everolimus—Dizziness—Ezetimibe—atherosclerosis	0.000328	0.000863	CcSEcCtD
Everolimus—Diarrhoea—Simvastatin—atherosclerosis	0.000324	0.000852	CcSEcCtD
Everolimus—Vomiting—Lovastatin—atherosclerosis	0.000322	0.000846	CcSEcCtD
Everolimus—Hypersensitivity—Niacin—atherosclerosis	0.00032	0.000842	CcSEcCtD
Everolimus—Rash—Lovastatin—atherosclerosis	0.000319	0.000839	CcSEcCtD
Everolimus—Dermatitis—Lovastatin—atherosclerosis	0.000319	0.000838	CcSEcCtD
Everolimus—Headache—Lovastatin—atherosclerosis	0.000317	0.000834	CcSEcCtD
Everolimus—Vomiting—Ezetimibe—atherosclerosis	0.000316	0.00083	CcSEcCtD
Everolimus—Hypersensitivity—Pravastatin—atherosclerosis	0.000315	0.000829	CcSEcCtD
Everolimus—Dizziness—Simvastatin—atherosclerosis	0.000313	0.000823	CcSEcCtD
Everolimus—Rash—Ezetimibe—atherosclerosis	0.000313	0.000823	CcSEcCtD
Everolimus—Dermatitis—Ezetimibe—atherosclerosis	0.000313	0.000822	CcSEcCtD
Everolimus—Asthenia—Niacin—atherosclerosis	0.000312	0.00082	CcSEcCtD
Everolimus—Headache—Ezetimibe—atherosclerosis	0.000311	0.000818	CcSEcCtD
Everolimus—Pruritus—Niacin—atherosclerosis	0.000308	0.000809	CcSEcCtD
Everolimus—Asthenia—Pravastatin—atherosclerosis	0.000307	0.000807	CcSEcCtD
Everolimus—Pruritus—Pravastatin—atherosclerosis	0.000303	0.000796	CcSEcCtD
Everolimus—Vomiting—Simvastatin—atherosclerosis	0.000301	0.000791	CcSEcCtD
Everolimus—Nausea—Lovastatin—atherosclerosis	0.000301	0.00079	CcSEcCtD
Everolimus—Rash—Simvastatin—atherosclerosis	0.000299	0.000785	CcSEcCtD
Everolimus—Dermatitis—Simvastatin—atherosclerosis	0.000298	0.000784	CcSEcCtD
Everolimus—Diarrhoea—Niacin—atherosclerosis	0.000298	0.000782	CcSEcCtD
Everolimus—Headache—Simvastatin—atherosclerosis	0.000297	0.00078	CcSEcCtD
Everolimus—Nausea—Ezetimibe—atherosclerosis	0.000295	0.000775	CcSEcCtD
Everolimus—Diarrhoea—Pravastatin—atherosclerosis	0.000293	0.00077	CcSEcCtD
Everolimus—Dizziness—Niacin—atherosclerosis	0.000288	0.000756	CcSEcCtD
Everolimus—Dizziness—Pravastatin—atherosclerosis	0.000283	0.000744	CcSEcCtD
Everolimus—Nausea—Simvastatin—atherosclerosis	0.000281	0.000739	CcSEcCtD
Everolimus—Vomiting—Niacin—atherosclerosis	0.000277	0.000727	CcSEcCtD
Everolimus—Rash—Niacin—atherosclerosis	0.000274	0.000721	CcSEcCtD
Everolimus—Dermatitis—Niacin—atherosclerosis	0.000274	0.00072	CcSEcCtD
Everolimus—Headache—Niacin—atherosclerosis	0.000272	0.000716	CcSEcCtD
Everolimus—Vomiting—Pravastatin—atherosclerosis	0.000272	0.000715	CcSEcCtD
Everolimus—Rash—Pravastatin—atherosclerosis	0.00027	0.000709	CcSEcCtD
Everolimus—Dermatitis—Pravastatin—atherosclerosis	0.00027	0.000709	CcSEcCtD
Everolimus—Headache—Pravastatin—atherosclerosis	0.000268	0.000705	CcSEcCtD
Everolimus—Nausea—Niacin—atherosclerosis	0.000258	0.000679	CcSEcCtD
Everolimus—Nausea—Pravastatin—atherosclerosis	0.000254	0.000668	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCL4—atherosclerosis	9.59e-05	0.000431	CbGpPWpGaD
Everolimus—MTOR—Disease—LDLR—atherosclerosis	9.58e-05	0.000431	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—atherosclerosis	9.56e-05	0.00043	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—atherosclerosis	9.51e-05	0.000428	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—atherosclerosis	9.47e-05	0.000426	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—atherosclerosis	9.46e-05	0.000426	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK8—atherosclerosis	9.45e-05	0.000425	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—atherosclerosis	9.42e-05	0.000424	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—atherosclerosis	9.42e-05	0.000424	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—atherosclerosis	9.38e-05	0.000422	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—atherosclerosis	9.3e-05	0.000419	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—atherosclerosis	9.28e-05	0.000418	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PDGFB—atherosclerosis	9.26e-05	0.000417	CbGpPWpGaD
Everolimus—MTOR—Disease—HSPA1B—atherosclerosis	9.25e-05	0.000416	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—atherosclerosis	9.23e-05	0.000415	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PDGFB—atherosclerosis	9.22e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—atherosclerosis	9.21e-05	0.000415	CbGpPWpGaD
Everolimus—MTOR—Immune System—CCR2—atherosclerosis	9.16e-05	0.000412	CbGpPWpGaD
Everolimus—MTOR—Immune System—CYBA—atherosclerosis	9.12e-05	0.00041	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—atherosclerosis	9.03e-05	0.000407	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KNG1—atherosclerosis	9.01e-05	0.000405	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA2—atherosclerosis	8.96e-05	0.000403	CbGpPWpGaD
Everolimus—MTOR—Disease—NCF1—atherosclerosis	8.96e-05	0.000403	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR1—atherosclerosis	8.95e-05	0.000403	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—atherosclerosis	8.86e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—atherosclerosis	8.86e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—atherosclerosis	8.86e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—atherosclerosis	8.86e-05	0.000399	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—atherosclerosis	8.82e-05	0.000397	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—atherosclerosis	8.82e-05	0.000397	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MAPK3—atherosclerosis	8.8e-05	0.000396	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—atherosclerosis	8.78e-05	0.000395	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—atherosclerosis	8.77e-05	0.000395	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—atherosclerosis	8.77e-05	0.000395	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CAV1—atherosclerosis	8.74e-05	0.000393	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—atherosclerosis	8.73e-05	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PLG—atherosclerosis	8.73e-05	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOA1—atherosclerosis	8.72e-05	0.000392	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—atherosclerosis	8.7e-05	0.000392	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—atherosclerosis	8.69e-05	0.000391	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—atherosclerosis	8.66e-05	0.00039	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—atherosclerosis	8.64e-05	0.000389	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—atherosclerosis	8.56e-05	0.000385	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—UTS2—atherosclerosis	8.54e-05	0.000385	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40—atherosclerosis	8.52e-05	0.000383	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR2—atherosclerosis	8.52e-05	0.000383	CbGpPWpGaD
Everolimus—MTOR—Disease—CYBA—atherosclerosis	8.42e-05	0.000379	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ICAM1—atherosclerosis	8.32e-05	0.000374	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SOCS3—atherosclerosis	8.26e-05	0.000372	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK3—atherosclerosis	8.25e-05	0.000372	CbGpPWpGaD
Everolimus—MTOR—Disease—PARP1—atherosclerosis	8.24e-05	0.000371	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—atherosclerosis	8.22e-05	0.00037	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CX3CR1—atherosclerosis	8.19e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASR—atherosclerosis	8.19e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—atherosclerosis	8.17e-05	0.000368	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—atherosclerosis	8.17e-05	0.000368	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—atherosclerosis	8.17e-05	0.000368	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—atherosclerosis	8.1e-05	0.000365	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CX3CL1—atherosclerosis	8.03e-05	0.000362	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—atherosclerosis	8.03e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—atherosclerosis	7.99e-05	0.00036	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP3—atherosclerosis	7.98e-05	0.000359	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF2—atherosclerosis	7.95e-05	0.000358	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—atherosclerosis	7.85e-05	0.000353	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	7.83e-05	0.000352	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	7.72e-05	0.000347	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOB—atherosclerosis	7.71e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD14—atherosclerosis	7.68e-05	0.000346	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CNR2—atherosclerosis	7.62e-05	0.000343	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EDN1—atherosclerosis	7.59e-05	0.000342	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—atherosclerosis	7.56e-05	0.00034	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL5—atherosclerosis	7.53e-05	0.000339	CbGpPWpGaD
Everolimus—FKBP1A—Disease—INS—atherosclerosis	7.53e-05	0.000339	CbGpPWpGaD
Everolimus—MTOR—Immune System—VCAM1—atherosclerosis	7.41e-05	0.000333	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LPL—atherosclerosis	7.37e-05	0.000332	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—atherosclerosis	7.24e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Immune System—SOCS3—atherosclerosis	7.19e-05	0.000324	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCG—atherosclerosis	7.16e-05	0.000322	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SPP1—atherosclerosis	6.98e-05	0.000314	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—atherosclerosis	6.92e-05	0.000311	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VWF—atherosclerosis	6.79e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOC3—atherosclerosis	6.75e-05	0.000304	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LDLR—atherosclerosis	6.71e-05	0.000302	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—atherosclerosis	6.61e-05	0.000297	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—atherosclerosis	6.55e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL3—atherosclerosis	6.55e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—atherosclerosis	6.53e-05	0.000294	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PDGFB—atherosclerosis	6.45e-05	0.000291	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—atherosclerosis	6.43e-05	0.00029	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGT—atherosclerosis	6.3e-05	0.000284	CbGpPWpGaD
Everolimus—MTOR—Immune System—AGER—atherosclerosis	6.29e-05	0.000283	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCF1—atherosclerosis	6.27e-05	0.000282	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCG—atherosclerosis	6.23e-05	0.00028	CbGpPWpGaD
Everolimus—MTOR—Disease—APOB—atherosclerosis	6.2e-05	0.000279	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—atherosclerosis	6.17e-05	0.000278	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—atherosclerosis	6.17e-05	0.000278	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—atherosclerosis	6.12e-05	0.000275	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOA1—atherosclerosis	6.1e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD36—atherosclerosis	6.09e-05	0.000274	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—atherosclerosis	6.04e-05	0.000272	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—atherosclerosis	6.03e-05	0.000272	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDNRA—atherosclerosis	5.92e-05	0.000267	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR2—atherosclerosis	5.92e-05	0.000267	CbGpPWpGaD
Everolimus—MTOR—Disease—LPL—atherosclerosis	5.92e-05	0.000266	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CYBA—atherosclerosis	5.9e-05	0.000265	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—atherosclerosis	5.89e-05	0.000265	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—atherosclerosis	5.82e-05	0.000262	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLAT—atherosclerosis	5.77e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PARP1—atherosclerosis	5.77e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GHRL—atherosclerosis	5.77e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCG—atherosclerosis	5.75e-05	0.000259	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFB—atherosclerosis	5.61e-05	0.000253	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—atherosclerosis	5.57e-05	0.000251	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—atherosclerosis	5.57e-05	0.000251	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	5.55e-05	0.00025	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—atherosclerosis	5.49e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKB1—atherosclerosis	5.48e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK8—atherosclerosis	5.39e-05	0.000243	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—atherosclerosis	5.33e-05	0.00024	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INS—atherosclerosis	5.27e-05	0.000237	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NFKB1—atherosclerosis	5.27e-05	0.000237	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—atherosclerosis	5.26e-05	0.000237	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLTP—atherosclerosis	5.22e-05	0.000235	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—atherosclerosis	5.19e-05	0.000234	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFB—atherosclerosis	5.18e-05	0.000233	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—atherosclerosis	5.1e-05	0.00023	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KNG1—atherosclerosis	5.07e-05	0.000228	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—atherosclerosis	5.04e-05	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—atherosclerosis	5.04e-05	0.000227	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—atherosclerosis	4.96e-05	0.000223	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—atherosclerosis	4.91e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLG—atherosclerosis	4.91e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—atherosclerosis	4.9e-05	0.000221	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—atherosclerosis	4.84e-05	0.000218	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—atherosclerosis	4.71e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—atherosclerosis	4.71e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS3—atherosclerosis	4.65e-05	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—atherosclerosis	4.63e-05	0.000208	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—atherosclerosis	4.62e-05	0.000208	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LTA4H—atherosclerosis	4.52e-05	0.000204	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG8—atherosclerosis	4.52e-05	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—atherosclerosis	4.5e-05	0.000203	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP3—atherosclerosis	4.49e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—atherosclerosis	4.47e-05	0.000201	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—atherosclerosis	4.37e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOB—atherosclerosis	4.34e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—atherosclerosis	4.27e-05	0.000192	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL5—atherosclerosis	4.24e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Disease—INS—atherosclerosis	4.24e-05	0.000191	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—atherosclerosis	4.14e-05	0.000186	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—atherosclerosis	4.1e-05	0.000185	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCG—atherosclerosis	4.03e-05	0.000181	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SPP1—atherosclerosis	3.92e-05	0.000177	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—atherosclerosis	3.89e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—atherosclerosis	3.84e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—atherosclerosis	3.71e-05	0.000167	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—atherosclerosis	3.71e-05	0.000167	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKB1—atherosclerosis	3.67e-05	0.000165	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFB—atherosclerosis	3.63e-05	0.000163	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—atherosclerosis	3.61e-05	0.000162	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG1—atherosclerosis	3.58e-05	0.000161	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—atherosclerosis	3.54e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—atherosclerosis	3.47e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—atherosclerosis	3.47e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—atherosclerosis	3.44e-05	0.000155	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—atherosclerosis	3.44e-05	0.000155	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—atherosclerosis	3.43e-05	0.000154	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—atherosclerosis	3.42e-05	0.000154	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—atherosclerosis	3.4e-05	0.000153	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FABP4—atherosclerosis	3.36e-05	0.000151	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LCAT—atherosclerosis	3.36e-05	0.000151	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—atherosclerosis	3.33e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—atherosclerosis	3.32e-05	0.000149	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA4—atherosclerosis	3.3e-05	0.000149	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—atherosclerosis	3.3e-05	0.000149	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—atherosclerosis	3.29e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—atherosclerosis	3.27e-05	0.000147	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP7A1—atherosclerosis	3.24e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKB1—atherosclerosis	3.19e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—atherosclerosis	3.18e-05	0.000143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—atherosclerosis	3.15e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—atherosclerosis	3.14e-05	0.000141	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—atherosclerosis	3.13e-05	0.000141	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—atherosclerosis	3.06e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—atherosclerosis	3.05e-05	0.000137	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—atherosclerosis	3.04e-05	0.000137	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INS—atherosclerosis	2.97e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—atherosclerosis	2.92e-05	0.000131	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—atherosclerosis	2.87e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—atherosclerosis	2.87e-05	0.000129	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.84e-05	0.000128	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.84e-05	0.000128	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA2—atherosclerosis	2.84e-05	0.000128	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.84e-05	0.000128	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.81e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—atherosclerosis	2.74e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—atherosclerosis	2.72e-05	0.000123	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPA—atherosclerosis	2.71e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—atherosclerosis	2.65e-05	0.000119	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BGN—atherosclerosis	2.63e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—atherosclerosis	2.6e-05	0.000117	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA5—atherosclerosis	2.6e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—atherosclerosis	2.53e-05	0.000114	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.5e-05	0.000113	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—atherosclerosis	2.46e-05	0.000111	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.42e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—atherosclerosis	2.31e-05	0.000104	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—atherosclerosis	2.3e-05	0.000104	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.17e-05	9.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPC—atherosclerosis	2.15e-05	9.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOC3—atherosclerosis	2.14e-05	9.63e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LDLR—atherosclerosis	2.13e-05	9.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—atherosclerosis	2.13e-05	9.57e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—atherosclerosis	2.09e-05	9.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CETP—atherosclerosis	2.08e-05	9.35e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKB1—atherosclerosis	2.06e-05	9.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—atherosclerosis	2.03e-05	9.14e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—atherosclerosis	2e-05	9.02e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.99e-05	8.95e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.88e-05	8.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—atherosclerosis	1.87e-05	8.43e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—atherosclerosis	1.86e-05	8.35e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—atherosclerosis	1.85e-05	8.33e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—atherosclerosis	1.85e-05	8.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—atherosclerosis	1.77e-05	7.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—atherosclerosis	1.72e-05	7.74e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—atherosclerosis	1.71e-05	7.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.67e-05	7.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.44e-05	6.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOB—atherosclerosis	1.38e-05	6.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.34e-05	6.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—atherosclerosis	1.31e-05	5.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—atherosclerosis	1.3e-05	5.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—atherosclerosis	1.28e-05	5.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—atherosclerosis	1.25e-05	5.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—atherosclerosis	1.2e-05	5.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.18e-05	5.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARA—atherosclerosis	1.16e-05	5.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—atherosclerosis	1.12e-05	5.06e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—atherosclerosis	1.1e-05	4.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—atherosclerosis	1.09e-05	4.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—atherosclerosis	1.09e-05	4.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—atherosclerosis	9.94e-06	4.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—atherosclerosis	9.59e-06	4.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INS—atherosclerosis	9.41e-06	4.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—atherosclerosis	8.63e-06	3.88e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—atherosclerosis	8.25e-06	3.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—atherosclerosis	7.55e-06	3.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—atherosclerosis	3.79e-06	1.71e-05	CbGpPWpGaD
